Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: LNA antisense oligonucleotides - Enzon/Roche

Next Previous
Drug Profile

Research programme: LNA antisense oligonucleotides - Enzon/Roche

Alternative Names: Cur 813; EZN-3889; EZN-3892; EZN-3920; EZN-4150; EZN-4482; EZN-4496; PEG-LNA-ON; SPC2004; SPC3920

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Androgen receptor antagonists; Antisense RNA inhibitors; Beta catenin inhibitors; ERBB-3 receptor modulators; Proto-oncogene protein c-bcl-2 modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Oct 2025 Preclinical development is ongoing for Cancer in Denmark (Enzon pharmaceuticals pipeline, October 2025)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (IV)
  • 28 Oct 2013 Enzon Pharmaceuticals terminates its licence for the research programme

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top